Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 10, 2026Neurosurgery

The Revolve Study: A Multicenter Registry Using the Flow Diverter Surpass Evolve® Device for the Endovascular Treatment of Intracranial Aneurysms

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMariangela PianoAVAlessio VitielloELEmilio Lozupone

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates safety and efficacy of Surpass Evolve device in intracranial aneurysms, suggesting promising results.

Key Points

  • This study assesses the feasibility, safety, and efficacy of the Surpass Evolve flow diverter in treating intracranial aneurysms.
  • 275 aneurysms treated with Surpass Evolve flow diverter from May 2019 to December 2022 across 28 Italian centers.
  • Clinical and imaging follow-ups were conducted up to 24 months, including assessments by a central Core Lab.
  • Evaluation of success rates concerning device deployment and occlusion at mid-term and long-term follow-ups.
  • Complete or near-complete occlusion was achieved in 66% of aneurysms at mid-term, increasing to 92% at long-term.
  • Device-related mortality was noted at 0.7%, with a morbidity of 5.4%.
  • 82% of aneurysms were considered cured based on mass criteria, with only 0.5% exhibiting sac enlargement.

Cite This Study

Piano et al. (2026) studied this question.

synapsesocial.com/papers/6a28ff6a6f82f25be989c5f9https://doi.org/10.1227/neu.0000000000004113
View Full Paper
Ask AI
Bookmark
Share